| Literature DB >> 22935483 |
Jodie L Babitt1, Herbert Y Lin.
Abstract
Anemia is a common feature of CKD associated with poor outcomes. The current management of patients with anemia in CKD is controversial, with recent clinical trials demonstrating increased morbidity and mortality related to erythropoiesis stimulating agents. Here, we examine recent insights into the molecular mechanisms underlying anemia of CKD. These insights hold promise for the development of new diagnostic tests and therapies that directly target the pathophysiologic processes underlying this form of anemia.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22935483 PMCID: PMC3458456 DOI: 10.1681/ASN.2011111078
Source DB: PubMed Journal: J Am Soc Nephrol ISSN: 1046-6673 Impact factor: 10.121